Business Wire

CO-TEKNOWLEDGE

9.4.2024 14:01:32 CEST | Business Wire | Press release

Share
Welcome to TeKnowledge: Accelerating Progress. Securing Futures.

TeKnowledge marks its global debut today, bringing together the formidable strengths of Cytek Security, Tek Experts, and Elev8 into a single, unified powerhouse. Each entity contributes its specialized expertise—Cytek Security in cutting-edge cybersecurity readiness, Tek Experts in unparalleled enterprise technical managed services, and Elev8 in innovative technical skilling—creating a comprehensive portfolio under TeKnowledge that offers end-to-end digital transformation services. This strategic amalgamation heralds the beginning of a new era in tech services, where TeKnowledge stands as the transformative catalyst for digital evolution, providing governments and enterprises worldwide with unparalleled cybersecurity services, advanced technical skilling, and enterprise technical managed services at scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409688971/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TeKnowledge: Uniting Cytek Security, Tek Experts, and Elev8 under one banner to pioneer the future of secure digital transformation and tech talent empowerment across the globe (Graphic: Business Wire)

Backed by over a decade of pioneering achievements in the tech services industry and a distinguished roster of government and enterprise customers worldwide, TeKnowledge is uniquely equipped to navigate the complexities of digital modernization. By integrating these powerhouse brands, TeKnowledge tackles the critical challenges of bridging the tech talent gap and expediting digital imperatives, providing a holistic suite of services tailored to bolster cybersecurity defenses, cultivate essential technical skills, and deliver expert technical managed services to streamline and accelerate digital strategies.

Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services. Drawing upon her notable success at various tech giants including Microsoft and HP, Aileen has swiftly positioned TeKnowledge as a leader in secure and scalable technology solutions. In her first strategic initiative, Aileen has built an exceptional leadership team, merging seasoned executives from Tek Experts, Elev8, and Cytek, and enriched by strategic new appointments. This includes bringing on board Jyllene Miller as Chief Revenue and Growth Officer, tapping into her extensive experience in growth strategies and market development garnered at numerous Fortune 500 companies to propel TeKnowledge's global expansion. The team is further bolstered by Eric Schifflers as Chief Information Security Officer (CISO), whose vast experience across global organizations like NATO, Ria Money Transfer, and Roche, amplifies TeKnowledge's cybersecurity defenses and strategic security initiatives.

The executive leadership team at TeKnowledge, a dynamic group of seasoned leaders, embodies a wealth of diverse expertise, driving the company's strategic vision across public and private sectors. Their collective skills in global operations, cybersecurity, digital transformation, and customer experience, honed over decades, are crucial in navigating the digital landscape's complexities. This team's unified approach is setting new industry standards, establishing TeKnowledge as a leader in digital services and a catalyst for transformative growth and resilience in the digital era.

"A unified TeKnowledge signifies a major shift in digital transformation services," states Aileen Allkins, President and CEO. "Bringing together the expertise of Cytek Security, Tek Experts, and Elev8 under the TeKnowledge umbrella, creates a synergy that benefits our customers as we enhance our delivery, achieving faster, more impactful outcomes. This positions us to effectively tackle the tech talent gap and pace of digital innovation. Offering a comprehensive suite of elite cybersecurity services, top-tier digital skilling, and scalable technical managed services, TeKnowledge is committed to guiding governments and enterprises worldwide through the complexities of digital transformation. Our approach integrates these services seamlessly, maximizing efficiency, simplifying processes, and accelerating the achievement of strategic imperatives with unparalleled precision and efficacy."

How TeKnowledge is Bridging Global Divides with Local Impact:

  • Optimized Managed Technical Services: TeKnowledge (f.k.a. Tek Experts) stands out with its superior operational excellence and agile solutions, supported by a global network of professionals, including a significant presence in emerging markets. Our enterprise managed services are distinguished by their ability to seamlessly integrate and scale, ensuring organizations achieve operational superiority and strategic success in the digital landscape.
  • Precision Technical Skilling: Directly addressing the global talent gap, TeKnowledge's (f.k.a. Elev8) custom training programs are strategically designed to equip both the current and future generations with the skills needed to navigate and excel in the ever-evolving tech landscape, preparing them for the challenges and opportunities that lie ahead.
  • Dynamic Cybersecurity Services: With an all-encompassing suite of advisory and Managed Security Services (MSS) offerings, TeKnowledge (f.k.a. Cytek Security) equips customers with dynamic defenses against the evolving cyber landscape.

The launch of TeKnowledge heralds an important evolution in the global digital landscape, emphasizing a future where digital security and operational excellence transform from aspirations into baseline expectations worldwide. At the core of this transformation is the robust talent—engineers supporting engineers, and developers supporting developers—to ensure unparalleled expertise and collaboration in tackling the digital challenges ahead.

To learn more about TeKnowledge, visit www.TeKnowledge.com.

About TeKnowledge: Accelerating Progress, Securing Futures.

TeKnowledge stands as the transformative catalyst for digital evolution, enabling governments and enterprises worldwide to navigate the challenges with digital transformation today and tomorrow with elite cybersecurity implementation and managed security services (MSS), top-tier digital skilling, and technical managed services at scale. TeKnowledge envisions a world where every government and enterprise is empowered with the most advanced, secure, and accessible technology solutions. Our commitment to technology enablement, security, and advancement positions us uniquely in the market, ensuring our customers are equipped to achieve their strategic imperatives in the digital age with confidence and competitive advantage. Start your journey towards digital excellence by visiting TeKnowledge.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409688971/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye